These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 25498772)

  • 1. Optimizing the position and use of omalizumab for severe persistent allergic asthma using cost-effectiveness analysis.
    Faria R; McKenna C; Palmer S
    Value Health; 2014 Dec; 17(8):772-82. PubMed ID: 25498772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation.
    Norman G; Faria R; Paton F; Llewellyn A; Fox D; Palmer S; Clifton I; Paton J; Woolacott N; McKenna C
    Health Technol Assess; 2013 Nov; 17(52):1-342. PubMed ID: 24267198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of omalizumab in severe persistent asthma in Spain: a real-life perspective.
    Levy AN; García A Ruiz AJ; García-Agua Soler N; Sanjuan MV
    J Asthma; 2015 Mar; 52(2):205-10. PubMed ID: 24995661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years.
    Walker S; Burch J; McKenna C; Wright K; Griffin S; Woolacott N
    Health Technol Assess; 2011 May; 15 Suppl 1():13-21. PubMed ID: 21609649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years: a NICE single technology appraisal.
    Burch J; Griffin S; McKenna C; Walker S; Paton J; Wright K; Woolacott N
    Pharmacoeconomics; 2012 Nov; 30(11):991-1004. PubMed ID: 22950547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of omalizumab for uncontrolled allergic asthma in the Netherlands.
    van Nooten F; Stern S; Braunstahl GJ; Thompson C; Groot M; Brown RE
    J Med Econ; 2013; 16(3):342-8. PubMed ID: 23216016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective.
    Campbell JD; Spackman DE; Sullivan SD
    Allergy; 2010 Sep; 65(9):1141-8. PubMed ID: 20148804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 36-month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy.
    Dal Negro RW; Tognella S; Pradelli L
    J Asthma; 2012 Oct; 49(8):843-8. PubMed ID: 22954018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Bermejo I; Stevenson M; Cooper K; Harnan S; Hamilton J; Clowes M; Carroll C; Harrison T; Saha S
    Pharmacoeconomics; 2018 Feb; 36(2):131-144. PubMed ID: 28933002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden.
    Dewilde S; Turk F; Tambour M; Sandström T
    Curr Med Res Opin; 2006 Sep; 22(9):1765-76. PubMed ID: 16968580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The "e" in cost-effectiveness analyses. A case study of omalizumab efficacy and effectiveness for cost-effectiveness analysis evidence.
    Campbell JD; McQueen RB; Briggs A
    Ann Am Thorac Soc; 2014 Feb; 11 Suppl 2():S105-11. PubMed ID: 24559022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omalizumab for the treatment of severe persistent allergic asthma.
    Jones J; Shepherd J; Hartwell D; Harris P; Cooper K; Takeda A; Davidson P
    Health Technol Assess; 2009 Sep; 13 Suppl 2():31-9. PubMed ID: 19804687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of omalizumab add-on to standard-of-care therapy in patients with uncontrolled severe allergic asthma in a Brazilian healthcare setting.
    Suzuki C; Lopes da Silva N; Kumar P; Pathak P; Ong SH
    J Med Econ; 2017 Aug; 20(8):832-839. PubMed ID: 28532191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and pharmacoeconomic aspects of omalizumab: a 4-year follow-up.
    Menzella F; Facciolongo N; Piro R; Formisano D; Roggeri A; Simonazzi A; Castagnetti C; Carbonelli C; Zucchi L
    Ther Adv Respir Dis; 2012 Apr; 6(2):87-95. PubMed ID: 22323442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of omalizumab for the treatment of inadequately controlled severe allergic asthma in Chinese children.
    Zhou H; Lu Y; Wu B; Che D
    J Asthma; 2020 Jan; 57(1):87-94. PubMed ID: 30507328
    [No Abstract]   [Full Text] [Related]  

  • 16. Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma.
    Brown R; Turk F; Dale P; Bousquet J
    Allergy; 2007 Feb; 62(2):149-53. PubMed ID: 17298423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of omalizumab on emergency-department visits, hospitalizations, and corticosteroid use among patients with uncontrolled asthma.
    Lafeuille MH; Dean J; Zhang J; Duh MS; Gorsh B; Lefebvre P
    Ann Allergy Asthma Immunol; 2012 Jul; 109(1):59-64. PubMed ID: 22727159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness of Bronchial Thermoplasty, Omalizumab, and Standard Therapy for Moderate-to-Severe Allergic Asthma.
    Zafari Z; Sadatsafavi M; Marra CA; Chen W; FitzGerald JM
    PLoS One; 2016; 11(1):e0146003. PubMed ID: 26751790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma.
    Sullivan SD; Turk F
    Allergy; 2008 Jun; 63(6):670-84. PubMed ID: 18445184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis.
    Whittington MD; McQueen RB; Ollendorf DA; Tice JA; Chapman RH; Pearson SD; Campbell JD
    Ann Allergy Asthma Immunol; 2017 Feb; 118(2):220-225. PubMed ID: 27923549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.